Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The kainate receptor (KAR) is a subtype of ionotropic glutamate receptor that mediates fast excitatory synaptic transmission and modulates synaptic plasticity throughout the central nervous system (UniProt Consortium, 2023). These receptors are tetrameric assemblies composed of various combinations of five subunits, GRIK1 through GRIK5, which determine their specific biophysical properties and pharmacological profiles (NCBI Gene, 2024). Unlike other glutamate receptors, KARs function in both presynaptic and postsynaptic capacities, where they regulate the release of neurotransmitters such as GABA and glutamate, thereby fine-tuning neural circuit excitability (Lerma & Marques, 2013). Dysregulation of kainate receptor activity is strongly implicated in the pathophysiology of neurological and psychiatric disorders, most notably temporal lobe epilepsy, where overactivation contributes to neuronal hyperexcitability and excitotoxicity (Contractor et al., 2011). They are also associated with chronic pain, schizophrenia, and depression, making them significant targets for drug development (StatPearls, 2023). Pharmacological agents targeting KARs include selective antagonists like tezampanel and LY466195, which have been investigated for treating migraines and seizures, although achieving high selectivity over AMPA receptors remains a primary therapeutic challenge (PubChem, 2024).
Kainate receptors function as ligand-gated ion channels that open upon glutamate binding to allow the influx of sodium and calcium ions. Therapeutic strategies involve competitive antagonism at the glutamate binding site or non-competitive allosteric modulation to reduce pathological hyperexcitability.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glutamate receptor ionotropic, kainate type (KAR) (KAR).